Clinical Trial Update: REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression [Phase 2]

View source ↗

Summary

A phase 2 trial comparing regorafenib to tamoxifen in platinum-sensitive ovarian carcinoma with isolated biological progression has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Carcinoma

Drugs mentioned

• Regorafenib (regorafenib)
• Tamoxifen (tamoxifen)

Snippet

Sponsor: ARCAGY/ GINECO GROUP | Conditions: Ovarian Carcinoma | Phase 2 | Status: COMPLETED